|
Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer. |
|
|
Consulting or Advisory Role - Roche |
Speakers' Bureau - Roche; Sanofi |
Travel, Accommodations, Expenses - Ipsen; Novartis |
|
|
Honoraria - Boehringer Ingelheim; Novartis; Pierre Fabre; roche |
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pierre Fabre; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Celgene; Lilly; Merck; Roche; Sanofi |
Travel, Accommodations, Expenses - Amgen; Celgene; Merck; Roche |
|
|
|
Consulting or Advisory Role - Merck Serono; Roche; Teva |
Speakers' Bureau - Amgen; Hospira; Lilly; Novartis |
Research Funding - Pierre Fabre |
|
|
Honoraria - Amgen; Bayer; Celgene; Ipsen; Lilly; Merck; Novartis; Roche; Sanofi |
Consulting or Advisory Role - Amgen; Bayer; Celgene; Ipsen; Lilly; Merck; Roche; Sanofi |
Research Funding - Amgen; Merck; Roche |
Travel, Accommodations, Expenses - Amgen; Bayer; Celgene; Ipsen; Lilly; Merck; Novartis; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Merck Serono |
Consulting or Advisory Role - Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |